Mineralys Therapeutics shares are trading higher after Goldman Sachs initiated coverage on the stock with a Buy rating and announced a price target of $30.
Portfolio Pulse from Benzinga Newsdesk
Mineralys Therapeutics' stock (MLYS) is trading higher following Goldman Sachs' initiation of coverage with a Buy rating and a price target of $30.

April 02, 2024 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs initiated coverage on Mineralys Therapeutics with a Buy rating and a $30 price target, leading to a positive impact on the stock.
The initiation of coverage by a prominent investment bank like Goldman Sachs, especially with a Buy rating and a significant price target, typically leads to increased investor confidence and demand for the stock. This often results in a short-term price increase as the market reacts to the new information and the perceived endorsement from a major financial institution.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100